NEW YORK, Dec. 10 — Galapagos Genomics and Euroscreen, both based in Belgium, have partnered to identify ligands for new GPCRs, the firms said on Monday. The research collaboration will target so-called orphan GPCRs, those GPCRs without known ligands.
Using its PhenoSelect expression platform, Galapagos will provide its partner with a library of secreted proteins and peptides, each correlated with a human gene. Euroscreen will screen the compounds for ligands that activate orphan GPCRs with its AequoScreen assay system. Together, the two companies will license validated ligands to pharmaceutical or biotech companies.
Financial details of the collaboration were not disclosed.
Galapagos Genomics, based in Mechelen, is a privately held functional genomics firm. Its expression platform uses arrayed adenoviruses containing human genes to identify and validate targets.
Euroscreen, headquartered in Brussels, was founded as a spin-off of Brussels University in 1994. It is focused on GPCR research and discovery, and has developed a technology to use the jellyfish photoprotein aequorin to identify protein ligands in cell-based assays.